For example, the combination of CDK4/6 inhibitors with PI3K/AKT/mTOR pathway inhibitors such as alpelisib in breast cancer cell lines and patient-derived models has demonstrated that alpelisib can overcome resistance mediated by PI3K pathway activation [29]. Here, CDK4 is linked to breast carcinoma.